Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Chantal SaberianNoha Abdel-WahabAla AbudayyehHind RafeiJacinth JosephGabriela RondonLaura WhitedStephen GruschkusFaisal Fa'akMay DaherCristina KnapeHoussein SafaMahran ShoukierMaria E Suarez-AlmazorMegan MarcotulliKaysia LudfordAlison M GulbisMarina KonoplevaMaro OhanianFarhad RavandiGuillermo Garcia-ManeroBetul OranUday R PopatRotesh MehtaAmin M AlousiNaval DaverRichard ChamplinAdi DiabGheath Al-AtrashPublished in: Journal for immunotherapy of cancer (2022)
ICI therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after alloHCT may be a safe and feasible option. PTCy appears to decrease the incidence of acute GVHD in this cohort of patients.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- liver failure
- respiratory failure
- end stage renal disease
- risk factors
- ejection fraction
- aortic dissection
- high dose
- prognostic factors
- mesenchymal stem cells
- hepatitis b virus
- intensive care unit
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- bone marrow